Medical News

RSS

MEDTOX Scientific board approves special one-time dividend

MEDTOX Scientific, Inc. today announced that its board of directors approved a special one-time cash dividend of $1.25 per share. The special dividend will be payable on December 1, 2010, to stockholders of record on November 22, 2010.

12 Nov 2010

Agilent fourth quarter revenues increase 35% to $1.58 billion

Agilent Technologies Inc. today reported revenues of $1.58 billion for the fourth fiscal quarter ended Oct. 31, 2010, 35 percent above one year ago, or 26 percent excluding the effects of the Varian acquisition and recent divestitures. Fourth-quarter GAAP net income was $232 million, or $0.66 per diluted share. Last year's fourth-quarter GAAP net income was $25 million, or $0.07 per share.

12 Nov 2010

Cortex third quarter net loss decreases to $528,000

Cortex Pharmaceuticals, Inc. reported a net loss applicable to common stock of approximately $528,000, or $0.01 per share, for the quarter ended September 30, 2010, compared with a net loss applicable to common stock of approximately $3,243,000 or $0.06 per share, for the prior year quarter.

12 Nov 2010

Abaxis releases new Piccolo reagent disc panel

Abaxis, Inc., a medical products company manufacturing point-of-care blood analysis systems, today announced the release of a new Piccolo® reagent disc panel called BioChemistry Panel Plus. This new reagent disc will be used by healthcare professionals in conjunction with the Piccolo Xpress™ point-of-care analyzer.

12 Nov 2010

IBEC researchers discover new group of interacting partners for myelin-associated receptors

It's known that the development of neuronal diseases such as multiple sclerosis and Alzheimer's disease is connected with the levels of myelin - an insulating substance around nerve fibres - in the body, although the actual causes of these conditions remain unknown. Now researchers at IBEC have discovered a new group of interacting partners for myelin-associated receptors, which could shed light on the significance of imbalanced production or modifications of the substance.

12 Nov 2010

Labopharm receives notice of Activis' ANDA submission for generic OLEPTRO

Labopharm Inc. today announced that on November 11, 2010 it received notice from Actavis South Atlantic LLC advising that Actavis has submitted an Abbreviated New Drug Application (ANDA) to the U.S. Food and Drug Administration (FDA) for approval to market 150 and 300 mg generic versions of OLEPTRO™ (trazodone hydrochloride extended-release 150 and 300 mg tablets) in the United States.

12 Nov 2010

Targeted Genetics enters definitive agreements to acquire Biocontrol

Targeted Genetics Corporation, today announced that it has entered into definitive agreements related to the acquisition of Biocontrol Limited, or Biocontrol.

12 Nov 2010

VIMOVO granted marketing and pricing approval in the UK

POZEN Inc., a pharmaceutical company committed to transforming medicine that transforms lives, today announced that it has been notified by AstraZeneca that marketing and pricing approval for VIMOVO™ (naproxen/ esomeprazole magnesium) 500/20 mg modified-release tablets, has been granted in the United Kingdom (UK).

12 Nov 2010

EMS World Magazine announces winners of 2010 Top Innovation Awards

EMS World Magazine, the leading monthly publication for the emergency medical services market, has announced the winners of the 2010 Top Innovation Awards, which recognize the industry's most innovative products of the year. The winners were chosen by industry expert and EMS World Magazine Editorial Advisory Board Member Mike Smith, BS, MICP. The awards will be presented at the Texas EMS State Conference in Austin, TX, November 21-24.

12 Nov 2010

Amorfix second quarter net loss decreases to $25,728

Amorfix Life Sciences, a product development company focused on the development of diagnostics and therapeutics for misfolded protein diseases, today announced its operational and financial results for the three and six months ended September 30, 2010.

12 Nov 2010

Spectrum Pharmaceuticals ranked #23 on Deloitte's Technology Fast 500

Spectrum Pharmaceuticals, Inc., a biotechnology company with fully integrated commercial and drug development operations with a primary focus in oncology, today announced that it ranked #23 on Technology Fast 500™, Deloitte's ranking of 500 of the fastest growing technology, media, telecommunications, life sciences and clean technology companies in North America. Rankings are based on percentage of fiscal year revenue growing during the period from 2005-2009. Spectrum Pharmaceuticals grew 6,490% during this period.

12 Nov 2010

CytomX awarded $488,000 as grant under QTDP Program

CytomX Therapeutics, a biotechnology company focused on the development of proteolytically activated antibodies, today announced the receipt of two grants totaling more than $488,000 from the Qualifying Therapeutic Discovery Project (QTDP) Program. The grants are directed toward the company's lead preclinical programs targeting colon, head and neck, pancreatic and triple-negative breast cancers and glioblastoma multiforme (GBM).

12 Nov 2010

Soligenix third quarter revenues increase to $861,000

Soligenix, Inc., a late-stage biopharmaceutical company, announced today its financial results for the third quarter of 2010.

12 Nov 2010

Pro-Pharmaceuticals third quarter net loss decreases to $1,899,000

Pro-Pharmaceuticals, Inc., a developer of therapeutics that target Galectin receptors to treat cancer and fibrosis, today reported its financial results for the third quarter and the nine months ended September 30, 2010. These results are included in the Company's Quarterly Report on Form 10-Q, which has been filed with the SEC.

12 Nov 2010

Transgenomic awarded $1,070,453 grant under Patient Protection and Affordable Care Act

Transgenomic, Inc. today announced that it has been awarded a research and development grant totaling $1,070,453.32 from the U.S. government under HR: 3590 – Patient Protection and Affordable Care Act (the "Act") in immediately available funds. This is among the largest awards for any one company under the Act.

12 Nov 2010

NovaBay third quarter net loss increases to $1.6 million

NovaBay Pharmaceuticals, Inc., a clinical stage biotechnology company developing first-in-class, anti-infective compounds for the treatment and prevention of antibiotic-resistant infections, has reported third quarter financial results and highlighted the clinical progress of its in-house programs.

12 Nov 2010

EntreMed reports $2.1 million net loss for third quarter 2010

EntreMed, Inc., a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer, today reported results for the three- and nine-month periods ending September 30, 2010.

12 Nov 2010

First Edition: November 12, 2010

Today's headlines include examinations of Medicaid and state budget issues as well as the next round of the congressional health overhaul fight.

12 Nov 2010

Medical Facilities third quarter revenue increases 4.2% to $51.0 million

Medical Facilities Corporation, today reported its financial results for the three- and nine-month periods ended September 30, 2010. All amounts are expressed in U.S. dollars unless indicated otherwise.

12 Nov 2010

Alcohol consumption among young Spaniards linked to night-time violence

Night-time violence among young Spaniards is becoming ever more common, according to a research study carried out by the European Institute of Studies on Prevention. The study shows that 5.2% of young people carry weapons when they go out at night, 11.6% have been attacked or threatened, and 23% have got into a fight at some time.

12 Nov 2010